Bottom line
Is ARTSX a good fund? The bottom line
ARTSX is the Investor share class of Artisan Small Cap Fund, a managed small-cap mutual fund from Artisan Partners.
Annual fees run 1.25% — about $125 a year on every $10,000 invested, more expensive than 75% of small-cap funds we track.
It returned +8.3% over one year, −2.7% a year over five years, +10.4% a year over ten (as of Dec 31, 2025, per its prospectus).
With $958 million in net assets and 59 holdings, its largest position is Twist Bioscience Corp. (5.5%) and the top 10 make up 38.3% of the portfolio.
What stands out
- No front-end sales load
What to watch
- Expensive for its category (1.25%)
- 5-year return in the bottom quarter of its category
Updated Nov 19, 2026
What ARTSX invests in
The Fund seeks long-term capital growth.
The Funds investment team employs a fundamental investment process to construct a diversified portfolio of US small-cap growth companies. The team seeks to invest in companies that it believes possess franchise characteristics, are benefiting from an accelerating profit cycle and are trading at a discount to its estimate of private market value. The Funds investment process focuses on two distinct elementssecurity selection and capital allocation. The team overlays its investment process with sustainability considerations and broad knowledge of the global economy. Security Selection The team seeks to identify companies that have franchise characteristics (e.g., low cost production capability, possession of a proprietary asset, dominant market share or a defensible brand name), are benefiting from an accelerating profit cycle and are trading at a discount to the teams estimate of…
From the fund's prospectus (filed Aug 31, 2026).
ARTSX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| ARTSX | +8.3% | −2.7% | +10.4% |
| Small-Cap median | +7.6% | +7.0% | +9.2% |
Source: Fund prospectus, as of Dec 31, 2025
What ARTSX costs
On a $10,000 investment, ARTSX's 1.25% expense ratio costs about $125 a year. The prospectus estimates $1,511 in total costs over 10 years (assuming 5% annual returns). The median small-cap fund charges 0.99%.
ARTSX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Twist Bioscience Corp. | 5.55% |
| 2 | Modine Manufacturing Co. | 4.96% |
| 3 | Lattice Semiconductor Corp. | 4.42% |
| 4 | Compass, Inc. | 3.94% |
| 5 | Cognex Corp. | 3.64% |
| 6 | VSE Corp. | 3.43% |
| 7 | Ascendis Pharma A/S | 3.25% |
| 8 | SPX Technologies, Inc. | 3.12% |
| 9 | Marex Group plc | 3.01% |
| 10 | Ionis Pharmaceuticals, Inc. | 2.96% |
Source: SEC Form N-PORT, period ended Jun 30, 2026
The top 10 make up 38.3% of the fund. See all top 25 holdings and asset mix →